Investor conference call and webcast to discuss data being presented at ESMO and zoci clinical trial plans scheduled for ...
A phase 3 global trial is enrolling previously treated locally advanced/metastatic nonsquamous NSCLC to define DATROWAY efficacy and safety at scale. IDE034 is in open-label phase 1 ...
ASCO guidance for stage IV EGFR-mutant NSCLC supports initial combination regimens (osimertinib plus chemotherapy; amivantamab plus lazertinib) to improve disease control relative to monotherapy.
[Sportschosun, Reporter Jang Jong-ho] Heavy ion therapy is expanding beyond early-stage lung cancer to stage IV lung cancer in which the cancer has spread to other organs but the number of metastatic ...
LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the ...
Lung cancer remains the leading cause of cancer-related mortality worldwide. Although small cell lung cancer (SCLC) accounts for a smaller percentage of lung cancer cases, it has remained a ...
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center. In this episode ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results